Finder makes money from featured partners, but editorial opinions are our own.

How to buy Regeneron Pharmaceuticals (REGN) stocks in Canada

Learn how to easily invest in Regeneron Pharmaceuticals stocks.

Regeneronn REGN

Regeneron Pharmaceuticals is a biotechnology business based in the US. Regeneron Pharmaceuticals shares (REGN.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $937.61 – an increase of 3.78% over the previous day. Regeneron Pharmaceuticals employs 13,450 staff and has a trailing 12-month revenue of around $13.1 billion.

How to buy shares in Regeneron Pharmaceuticals

  1. Choose a platform. If you're a beginner, our stock trading platform picks below can help you choose.
  2. Open your account. Provide your personal information and sign up.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: REGN in this case.
  5. Research stocks. The platform should provide the latest information available.
  6. Buy your stocks. Place a market order or limit order with your preferred number of shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Best for Lowest Commissions

Go to site
Low margin rates
  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Best for Low Fees

Go to site
CA & US trading
  • Up to $2,400 cash reward
  • Low transaction fees
  • Easy-to-use app

Best for Beginners

Go to site
Free trades for young investors
  • Easy-to-use platform
  • Low fees
  • Student and young investor discounts

Is it a good time to buy Regeneron Pharmaceuticals stock?

Only you can make the decision on the time to leap... but here's some supporting information and analysis.

Use our graph to track the performance of REGN stocks over time.

Share price volatility

Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $684.8 up to $998.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.141. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).

Historical closes compared with the last close of $937.61

1 week (2024-04-25)6.16%
1 month (2024-04-02)-1.40%
3 months (2024-02-01)-0.72%
6 months (2023-11-02)14.78%
1 year (2023-05-02)16.74%
2 years (2022-05-02)41.96%
3 years (2021-05-02)91.89%
5 years (2019-05-02)178.31%

The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.

Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.

Is Regeneron Pharmaceuticals under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Regeneron Pharmaceuticals P/E ratio, PEG ratio and EBITDA

Regeneron Pharmaceuticals's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Regeneron Pharmaceuticals stocks trade at around 26x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4591. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $4.7 billion ($6.4 billion CAD).

The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site